US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Metsera Inc (MTSR): GLP-1 Boom Comes to the IPO Market with Explosive Debut

Metsera Inc (MTSR) Six Month Summary: The Bright Spot in a Quiet Biotech Year

Metsera, Inc. (MTSR): Peeking at the Prospectus for the Next Obesity and Metabolic Diseases Biotech

Metsera Inc (MTSR): Obesity Drug Company Seeking up to $1.8b IPO Valuation

Eli Lilly's Weight Loss Revolution: Is It Edging Out Novo Nordisk?

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>The GLP-1 market has experienced a recent boom and Metsera is capitalizing on this with a well-times IPO.</li>
<li>According to our sources, the deal is well-oversubscribed with the books closing Wednesday at 4pm for a Friday debut.</li>
<li>The company is seeking a mega valuation of$1.8b if priced at the high-end of the range. An IPO valuation at these levels would put the company in "rare-company".</li>
</ul>


The GLP-1 market has experienced a recent boom and Metsera is capitalizing on this with a well-times IPO.
According to our sources, the deal is well-oversubscribed with the books closing Wednesday at 4pm for a Friday debut.
The company is seeking a mega valuation of$1.8b if priced at the high-end of the range. An IPO valuation at these levels would put the company in "rare-company".


Metsera Inc (MTSR): Obesity Drug Biotech Order Book Is "Hot"; Set for Friday IPO Debut